Literature DB >> 8705682

A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides.

K Oishi1, H Tanaka, F Sonoda, S Borann, K Ahmed, Y Utsunomiya, K Watanabe, T Nagatake, M Vaneechoutte, G Verschraegen, K Matsumoto.   

Abstract

A hybrid cell line producing a monoclonal antibody (MAb) against Moraxella (Branhamella) catarrhalis lipopolysaccharide (LPS) was established. The specificity of the MAb 1B12 to purified rough LPSs from six strains of M. catarrhalis was ascertained by enzyme-linked immunosorbent assay (ELISA), competitive-inhibition ELISA, and immunoblotting. MAb 1B12 bound to live bacterial cells and culture supernatants from a total of 34 strains of M. catarrhalis, including 12 strains with different LPS serotypes. No cross-reactions with smooth and rough LPSs from selected enterobacterial and nonenterobacterial strains, with other respiratory pathogens, or with Neisseria species were observed. These data suggest that MAb 1B12 recognizes a common epitope of M. catarrhalis LPS which differs from serotype determinants.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8705682      PMCID： PMC170345          DOI： 10.1128/cdli.3.3.351-354.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  30 in total

1.  Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens.

Authors:  M Vaneechoutte; G Verschraegen; G Claeys; A M Van Den Abeele
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

2.  Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

Authors:  M Pollack; J K Chia; N L Koles; M Miller; G Guelde
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

3.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

4.  Neisseria catarrhalis endocarditis.

Authors:  D Douer; Y Danziger; J Pinkhas
Journal:  Ann Intern Med       Date:  1977-01       Impact factor: 25.391

5.  Improved techniques for the preparation of bacterial lipopolysaccharides.

Authors:  K G Johnson; M B Perry
Journal:  Can J Microbiol       Date:  1976-01       Impact factor: 2.419

6.  beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children.

Authors:  A L Kovatch; E R Wald; R H Michaels
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

7.  Studies on the cellular and free lipopolysaccharides from Branhamella catarrhalis.

Authors:  K G Johnson; I J McDonald; M B Perry
Journal:  Can J Microbiol       Date:  1976-04       Impact factor: 2.419

8.  Characterization of lipopolysaccharide of Haemophilus influenzae.

Authors:  A R Flesher; R A Insel
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

9.  Preliminary serologic evidence for a pathogenic role of Branhamella catarrhalis.

Authors:  M Leinonen; J Luotonen; E Herva; K Valkonen; P H Mäkelä
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

10.  Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C.

Authors:  P Edebrink; P E Jansson; M M Rahman; G Widmalm; T Holme; M Rahman
Journal:  Carbohydr Res       Date:  1995-01-17       Impact factor: 2.104
View more
  6 in total

1.  Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Authors:  Raina T Gergova; Ianko D Iankov; Iana H Haralambieva; Ivan G Mitov
Journal:  Curr Microbiol       Date:  2007-01-05       Impact factor: 2.188

Review 2.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.

Authors:  Andrew D Cox; Frank St Michael; Chantelle M Cairns; Suzanne Lacelle; Amy Lea Filion; Dhamodharan Neelamegan; Cory Q Wenzel; Heather Horan; James C Richards
Journal:  Glycoconj J       Date:  2011-05-18       Impact factor: 2.916

5.  Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis.

Authors:  W G Hu; J Chen; J C McMichael; X X Gu
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.

Authors:  Shengqing Yu; Hang Xie; Anup Datta; Natasha Naidu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.